Tapering Lupus Drugs in Stable Patients: Flare Risks Studied

Tapering is best reserved for those in complete remission with stable disease for at least 6 months, although many individual patient characteristics must be taken into account, experts say.

Related Keywords

Paris ,France General ,France ,National University Hospital ,Singapore General ,Singapore ,Toronto ,Ontario ,Canada ,Montreal ,Quebec ,Merck Serono ,Dafnad Gladman ,Danielj Wallace ,Lyann Nguyen ,Sasha Bernatsky ,Nathalie Costedoat ,Eli Lilly ,Los Angeles ,Bristol Myers Squibb ,Jiacai Cho ,Joant Merrill ,James Mcgill ,Glaxosmithkline ,Statistics At Paris City University ,Novartis ,University Of Toronto ,University Of Oklahoma Health Sciences Center ,Amgen ,Pfizer ,National Referral Center ,Mcgill University ,Astrazeneca ,Sinai Medical Center ,Schroeder Arthritis Institute ,Lancet Rheumatologyconcluded ,Nathalie Costedoat Chalumeau ,Rare Autoimmune ,Systemic Diseases ,Cochin Hospital ,Paris City University ,Lupus Low Disease Activity State ,Activity Index ,Physician Global Assessment ,Toronto Lupus Cohort ,Oklahoma Health Sciences Center ,Oklahoma City ,Cedars Sinai Medical Center ,Systemic Lupus Erythematosus ,Sale ,Remission ,Lupus ,Corticosteroid ,Toxicology ,Glucocorticosteroids ,Immunosuppressive Therapy ,Immunosuppressive Agents ,Immunosuppressive Drugs ,Rug Immunosuppressive ,Steroids ,Patient Safety ,Calcineurin Inhibitor ,Hands ,Hospitals ,Oklahoma ,Cardiovascular Imaging ,Ardiac Imaging ,V Imaging ,